
Neurocrine Biosciences (NBIX) Stock Forecast & Price Target
Neurocrine Biosciences (NBIX) Analyst Ratings
Bulls say
Neurocrine Biosciences is poised for success as their current portfolio of drugs is performing well, and they have a strong pipeline of drug candidates in development which could provide significant revenue growth in the future. Additionally, their recent acquisition of Soleno could further strengthen their product portfolio and revenue potential. The company also appears to be well-integrated in sustainability initiatives and has a strong governance structure to support their efforts in this area. However, there are potential risks to consider, such as potential setbacks in R&D or commercialization, emergence of new competitors, and financing issues. Overall, the company's positive growth outlook and strong position in the biopharmaceutical industry make them a promising investment option.
Bears say
Neurocrine Biosciences is facing potential downside risks due to slow growth in key products, failure of pipeline assets, and increased competition leading to a loss of market share and decline in pricing power. While Ingrezza still has potential for growth in tardive dyskinesia, reaching peak sales in 2029, there are risks such as the emergence of side effects and discounted pricing. The recent 1Q26 financial results exceeded expectations, but there are still risks to consider such as stability of Ingrezza sales, potential plateau in Crenessity sales, and potential headwinds in the competitive landscape.
This aggregate rating is based on analysts' research of Neurocrine Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Neurocrine Biosciences (NBIX) Analyst Forecast & Price Prediction
Start investing in Neurocrine Biosciences (NBIX)
Order type
Buy in
Order amount
Est. shares
0 shares